Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05606159
Other study ID # NZ-GHCD-2021-06
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date November 2023
Est. completion date December 2024

Study information

Verified date October 2023
Source Novozymes A/S
Contact Victoria Oyedokun, PhD
Phone +491723244702
Email vtoy@novozymes.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine whether a single strain capsulated probiotic, when used after standard C. difficile antibiotic therapy, is effective in reducing the risk of infection recurrence mediated by a decrease in colonization by toxigenic C. difficile. This study will include adults with a history of two episodes of C. difficile infection (CDI).


Description:

The goal of this multi-center randomized double-blinded placebo-controlled trial is to evaluate the tolerability and effect of a probiotic dietary supplement on the reduction of the risk of recurrent C. difficile infection in adults who have experienced two previous C. difficile infection episodes. The main aim of this study is to assess the effect of a probiotic dietary supplement on the colonization (cell counts) of C. difficile over time and also to assess the correlation between level of C. difficile colonization and recurrence of CDI. Approximately, 104 research subjects will be randomized into two arms and will use either one capsule daily of the probiotic supplement or placebo once daily with breakfast, for 8 weeks. All outcomes will be compared across the supplementation and placebo arm.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 104
Est. completion date December 2024
Est. primary completion date November 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Males and females = 18 years old 2. Medical record documentation of second or subsequent recurrent CDI episode, and received standard-of-care oral antibiotic therapy completed no more than 5 days prior date of enrollment. 3. Able to provide signed and dated informed consent or assent 4. Able to provide blood and fecal specimens Exclusion Criteria: 1. Current episode of CDI or delayed symptom resolution from previous reoccurrence (second episode), according to the physical exam and investigator assessment 2. Pregnancy or breastfeeding 3. Subjects presenting with active diarrhea (3 or more stools per 24-hour period) and within Bristol stool scale range of 5-7 4. Taking dietary supplement or therapeutic intervention which could significantly affect parameter(s) followed during the study (fibers, probiotics, prebiotics, symbiotic) according to the investigator or stopped in a too short period before the V1 visit (< 4 weeks) 5. Previous reaction, including anaphylaxis, to any substance in composition of the study product 6. Active, non-controlled intestinal disease such as Crohn's Disease, ulcerative colitis; celiac disease, or other chronic diarrheal illness 7. Patients with active Pancreatitis 8. Ostomized subjects, parenteral nutrition users 9. Under immunosuppressive therapy or any health condition causing immunosuppression (including active hematological malignancies, acquired immune deficiency syndrome (AIDS), recent solid organ transplant (within 90 days),under treatment for rejection 10. For women: Non menopausal with the same reliable contraception since at least 3 cycles before the beginning of the study and agreeing to keep it during the entire duration of the study or menopausal without or with hormone replacement therapy (estrogenic replacement therapy begun from less than 3 months excluded); 11. Pregnant or lactating women or intending to become pregnant within 3 months ahead

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Bacillus velezensis DSM 33864
1 probiotic capsule to be taken orally once a day, with breakfast, once a day for 8 weeks.
Placebo
1 microcrystalline cellulose-containing placebo capsule to be taken orally once a day with breakfast, for 8 weeks.

Locations

Country Name City State
United States Beaumont Hospital Royal Oak Michigan

Sponsors (2)

Lead Sponsor Collaborator
Novozymes A/S Estimates OY

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Incidence of adverse events Incidence of adverse events from baseline to 12 weeks 12 weeks
Other Changes in hemoglobin concentration Changes in hemoglobin concentration from baseline to 12 weeks determined by standard Full Blood Count (FBC) test 12 weeks
Other Changes in blood platelet levels Changes in blood platelet levels from baseline to 12 weeks determined by standard Full Blood Count (FBC) test 12 weeks
Other Changes in blood C-reactive protein (CRP) levels Changes in C-reactive levels from baseline to 12 weeks determined by standard blood CRP test 12 weeks
Other Changes in blood glucose levels Changes in blood glucose from baseline to 12 weeks determined by standard blood chemistry panel test 12 weeks
Other Changes in blood urea nitrogen (BUN) levels Changes in blood urea nitrogen levels from baseline to 12 weeks determined by standard blood chemistry panel test 12 weeks
Other Changes in blood creatinine levels Changes in blood creatinine levels from baseline to 12 weeks determined by standard blood chemistry panel test 12 weeks
Other Changes in blood calcium levels Changes in blood calcium levels from baseline to 12 weeks determined by standard blood chemistry panel test 12 weeks
Other Incidence of any diarrhea determined by the Bristol Stool Scale (score range 5-7) Incidence of any diarrhea determined by the Bristol Stool Scale (score range 5-7) 12 weeks
Other Incidence of gastrointestinal pain or discomfort determined by GSRS questionnaire Incidence of gastrointestinal pain or discomfort determined by GSRS questionnaire 12 weeks
Other Intestinal microbiome diversity including functional and resistome genes Change in intestinal microbiome composition assessed from fecal samples using Deep Shotgun sequencing method 8 weeks
Other Change in intestinal bile acid levels Change in bile acids assessed from fecal samples by UPLC-MS 12 weeks
Other Change in intestinal short-chain fatty-acid levels Change in short chain fatty acids assessed from fecal samples by GC-MS 12 weeks
Other Recovery rate of Bacillus velezensis assessed from fecal samples Recovery rate of probiotic Bacillus velezensis DSM33864 in fecal samples, determined by qPCR method 12 weeks
Primary C. difficile colonization Change in colonization (counts) of toxigenic C. difficile from baseline to 8 weeks determined by quantitative PCR 8 weeks
Secondary C. difficile colonization Change in colonization (counts) of toxigenic C. difficile determined by quantitative PCR 4 weeks
Secondary C.difficile colonization Change in colonization (counts) of toxigenic C.difficile determined by quantitative PCR 12 weeks
Secondary Presence and levels of C. difficile toxin in fecal samples Change in concentration of C. difficile Toxin A or B levels in fecal samples from baseline to week 4, week 8 and week 12 determined by enzyme immune assay method (EIA) 12 weeks
Secondary Quality of life assessment Change in average health-related quality of life scores at baseline, week 8 and 12, determined by EQ-5D-5L questionnaire 12 weeks
Secondary Reduction of the risk of rCDI Incidence of rCDI defined as an episode of diarrhea onset described by three or more unformed stools per 24 h as measured by the Bristol stool chart (types 5 to 7), and positive toxin assay result for C. difficile. 8 weeks
Secondary Reduction of the risk of rCDI Incidence of rCDI defined as an episode of diarrhea onset described by three or more unformed stools per 24 h as measured by the Bristol stool chart (types 5 to 7), and positive toxin assay result for C. difficile. 4 weeks
See also
  Status Clinical Trial Phase
Terminated NCT04000555 - Oral Vancomycin for Secondary Prophylaxis of Clostridium Difficile Infection (CDI) Phase 4
Terminated NCT03065374 - Treatment for Clostridium-difficile Infection With IMM529 Phase 1/Phase 2
Completed NCT03110133 - Efficacy, Safety, and Tolerability Study of Oral Full-Spectrum MicrobiotaTM (CP101) in Subjects With Recurrent C. Diff Phase 2
Recruiting NCT06237452 - VE303 for Prevention of Recurrent Clostridioides Difficile Infection Phase 3
Completed NCT03880539 - Bezlotoxumab (BEZLO) In Addition To Standard Of Care (SOC) Vancomycin For The Treatment of Multi-Recurrent Clostridium Difficile Infection Phase 4
Not yet recruiting NCT04415918 - Bezlotoxumab Efficacy and Tolerability in Cancer Patient Phase 4
Recruiting NCT03562741 - Outcomes and Data Collection for Fecal Microbiota Transplantation for the Treatment of Recurrent Clostridium Difficile N/A
Completed NCT03788434 - Phase 2 Study of VE303 for Prevention of Recurrent Clostridioides Difficile Infection Phase 2
Completed NCT04891965 - A Study of ART24 in Subjects Recently Cured of a Clostridioides Difficile Infection (CDI) Phase 1
Completed NCT04317963 - Real-world Evaluation of Bezlotoxumab for the Management of Clostridioides Difficile Infection
Completed NCT03617445 - Fecal Microbiota Transplantation for C. Difficile Infection in Solid Organ Transplant Recipients Phase 2
Recruiting NCT05831189 - A Multi-center, Single-arm Trial Exploring the Safety and Clinical Effectiveness of RBX2660 Administered by Colonoscopy to Adults With Recurrent Clostridioides Difficile Infection Phase 3